Serina Therapeutics (SER) CSO sells 3,227 shares after option exercise

Rhea-AI Filing Summary

Serina Therapeutics Chief Scientific Officer Randall Moreadith exercised stock options and immediately sold the resulting shares. On 12/16/2025, he exercised 3,227 stock options at an exercise price of $0.06 per share, receiving the same number of common shares. He then sold all 3,227 shares at a weighted average price of $2.9631 per share in multiple trades between $3.00 and $2.96, leaving him with 0 shares of common stock held directly.

Following this transaction, Moreadith continues to hold 361,959 stock options with an exercise price of $0.06 per share, which are fully vested and expire on 05/06/2031.

Insider Trade Summary

Net Seller: 3,227 shares ($9,562)

Net Sell 3 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 3,227 shs ($10K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,227	$0.00	--
Exercise	Common Stock	3,227	$0.06	$193.62
Sale	Common Stock	3,227	$2.9631	$10K

Holdings After Transaction: Stock Option (right to buy) — 361,959 shares (Direct); Common Stock — 3,227 shares (Direct)

Footnotes (1)

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $2.96. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The stock options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		M		3,227	A	$0.06	3,227	D
Common Stock	12/16/2025		S		3,227	D	$2.9631(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	12/16/2025		M			3,227	(2)	05/06/2031	Common Stock	3,227	$0	361,959	D

Explanation of Responses:

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $2.96. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Serina Therapeutics (SER) report for its Chief Scientific Officer?

Serina Therapeutics reported that its Chief Scientific Officer, Randall Moreadith, exercised 3,227 stock options at $0.06 per share on 12/16/2025 and sold the resulting 3,227 common shares the same day.

How many Serina Therapeutics shares did Randall Moreadith sell and at what price?

Randall Moreadith sold 3,227 shares of Serina Therapeutics common stock at a weighted average price of $2.9631 per share, in multiple trades ranging from $3.00 to $2.96 on 12/16/2025.

What stock options did Randall Moreadith exercise in December 2025 at Serina Therapeutics (SER)?

On 12/16/2025, Moreadith exercised 3,227 stock options with an exercise price of $0.06 per share, converting them into an equal number of Serina Therapeutics common shares before selling those shares.

How many Serina Therapeutics stock options does Randall Moreadith still hold after this transaction?

After the reported transactions, Randall Moreadith beneficially owns 361,959 stock options with an exercise price of $0.06 per share, all of which are fully vested and expire on 05/06/2031.

Does Randall Moreadith own any Serina Therapeutics (SER) common stock directly after this trade?

Following the exercise and sale on 12/16/2025, the Form 4 shows that Moreadith holds 0 shares of Serina Therapeutics common stock directly.

Were the Serina Therapeutics shares sold in a single trade or multiple trades?

The 3,227 shares were sold in multiple transactions, with prices ranging from $3.00 to $2.96 per share, resulting in a weighted average sale price of $2.9631 per share.